Curetopia has provided $ 1.77 million in financing to speed up treatments for rare diseases through a decentralized biotech model that Solana uses.
Fundraising, supported by more than 1,000 individual contributors, emphasizes a growing momentum in the Sector Decentralized Science (DESCI), especially in the midst of a persistent US freeze on traditional Sources of financing Such as the National Institutes of Health (NIH) and National Science Foundation (NSF).
The Curetopia DAO, launched on the Bio protocol With support from Binance, tries to tackle an estimated market for rare rarer issues of $ 1 trillion that are historically served behind the pharmaceutical companies. With the help of blockchain-based crowdfunding, Curetopia patients and researchers can enable rare diseases and researchers to jointly finance drug development projects, to share the ownership of resulting treatments through tokenization.
Curetopia recently identified a possible treatment for AARS2 progressive leuko -encephalopathy, a fatal mitochondrial disease without approved therapies. This discovery, resulting from the screening of 8,500 re -considers connections through yeast models, represents one of the first authorities of a research project supported by Crypto that may achieve commercialization.
Curetopia currently submits a provisional patent for this discovery. All proceeds from the subsequent commercialization are re -invested in the DAO.
The operational model of Curetopia includes direct involvement in patient communities, a strategy that is defended by founder Dr. Ethan Perlstein, a promotion of Harvard and former Y Combinator participant. Perlstein previously exhibited a cost-effective clinical development by promoting rare disease treatment to phase 3-investigations for $ 5 million-market lower than traditional pharmaceutical paths.
Perlstein emphasized that decentralized drug development enables patients and families to directly influence therapeutic development, which broke the cycle of neglected research by limited commercial stimuli.
Participants in the decentralized tests of Curetopia receive healing tokens and effectively become stakeholders in the therapies they help develop.
The model of Curetopia, which uses the re -use of drugs, tokenized intellectual property and community drivers tests, aims to accelerate the approval processes for regulations, which considerably reduces both time and financial costs compared to conventional drug development.
The DAO recently also collaborated with Combined brain and cinemas to unravel to offer services for the screening of drugs to organizations that represent more than 100 genetic neurological disorders.
With a focus on redeveloping drugs, Curetopia wants to benefit from legal benefits such as FDA Priority review vouchers and orphan medicinal use, which offer accelerated paths and stimuli for therapeutic with rare disease therapy.
